Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Monthly Archives: November 2015

First Prostate Cancer Patient Treated with Minimally Invasive HIFU on West Coast

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center November 18, 2015. San Francisco, CA – HIFU Prostate Services, LLC, a leading provider of minimally- invasive prostate cancer treatment, using High Intensity Focused Ultrasound (HIFU), announced that physician partner and Medical Director, Michael J. Lazar, MD [...]

November 18th, 2015|

Recently FDA approved HIFU for Prostate Cancer makes news in Kentucky

HIFU is making news all over the United States now that it has achieved FDA approval. In the news video below HIFU Prostate Services physician partner, Dr. John Jurige speaks with Louisville's news station, WHAS about HIFU for prostate cancer. Dr. Jurige treated the first patients in the US with HIFU outside of a clinical [...]

November 18th, 2015|

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of [...]

November 12th, 2015|

HIFU Prostate Services Names Michael J. Lazar, MD Medical Director

Nov. 4, 2015 -- HIFU Prostate Services (HPS) has named Dr. Michael Lazar as HPS Medical Director. As HPS Medical Director Dr. Lazar will provide medical guidance and proctoring to new physicians that are being trained on the Sonablate® HIFU system in surgery centers around the country. HIFU offers an effective treatment for localized prostate [...]

November 11th, 2015|

HIFU Now Available In the U.S. Ending a Long Awaited FDA Approval Process

After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of [...]

November 10th, 2015|